Tag: osteoarticular
Pherecydes Pharma announces the positive recommendation of the DSMB for the continuation of its phase II clinical study PhagoDAIR in osteoarticular infections on prostheses caused by Staphylococcus aureus – 2022-11-29 at 18:00
Nantes, November 29, 2022 – 6 p.m. CET – Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotechnology company specializing in precision phage therapy intended to treat antibiotic-resistant and/or complicated…